Recombinant CPA1 antibody (full length)

Catalog No. ABIN7877802

The Rabbit Monoclonal anti-CPA1 antibody is suitable to detect CPA1 in samples from Human. It has been validated for IHC (p).

Quick Overview for Recombinant CPA1 antibody (full length) (ABIN7877802)

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CPA1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: CPA1-8623R

Product Details anti-CPA1 Antibody

Binding Specificity: full length

Purpose: CPA1 Antibody / Carboxypeptidase A1 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CPA1 protein was used as the immunogen for the CPA1 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the CPA1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the CPA1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CPA1

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Alternative Name: CPA1

Background: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085